Reprocell and Medicines Discovery Catapult partner to speed drug development

Cells
The European branch of Japan’s Reprocell, which supports stem cell research and preclinical drug trials, is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms. (Pixabay)

The European branch of Japan’s Reprocell, which supports stem cell research and preclinical drug trials, is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms.

As part of the deal, Reprocell will provide live human tissue that will be used to predict how drugs will behave in patients and whether those compounds have a good chance of success in clinical trials. Reprocell will have access to Medicines Discovery’s virtual research and development platforms.

Financial terms of the partnership weren’t disclosed.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“Ethically sourced human tissue samples are such an important resource for the prediction of efficacy and safety of novel drug compounds and are becoming increasingly important in the area of precision medicine,” Dr. Karen Bingham, Reprocell’s COO, said in a statement. “It’s crucial that the (National Health Service), industry and academia work together through collaborations such as Medicines Discovery Catapult in order to maximize use of this precious resource.”

Last year, Medicines Discovery announced a partnership with the National Centre for the Replacement, Refinement & Reduction of Animals in Research to accelerate in vitro research models for new products as well as reduce the number of animals being used in research. It also partnered with AstraZeneca to develop the use of sound waves in mass spectrometry for drug discovery applications.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.